The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function
Open accessAbstract
A single dose of the anti-CD20 monoclonal antibody rituximab induces a nearly complete B cell depletion in peripheral blood, but not in secondary lymphoid organs. Modulation of this remaining B cell population due to rituximab treatment may contribute to the therapeutic effects of rituximab. To assess the in vivo effects of rituximab we used lymph nodes (LNs) collected during renal transplant surgery in patients who had received rituximab 4 weeks earlier in preparation for an ABO-incompatible transplantation. Rituximab treatment resulted in a lower percentage of naïve (IgD(+)CD27(-)) and a higher percentage of switched memory (IgD(-)CD27(+)) B cells. Remarkably, transitional (CD24(++)CD38(++)) B cells were virtually lacking in the LNs of rituximab-treated patients. Moreover, LN-derived B cells from rituximab-treated patients produced different amounts of various Ig-subclasses after anti-CD40/IL-21 stimulation ex vivo. Finally, after stimulation of allogeneic T cells with LN-derived B cells from rituximab-treated patients, the proliferated T cells showed a decreased production of IL-17. In conclusion, after treatment with rituximab there remains a B cell population with different functional capacities. Consequently, the effect of rituximab on the immune response will not only be determined by the extent of B cell depletion, but also by the functional properties of the remaining B cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blair, P. A., Noreña, L. Y., Flores-Borja, F., Rawlings, D. J., Isenberg, D. A., Ehrenstein, M. R., & Mauri, C. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.009 · Cited by 1,574
Iwata, Y., Matsushita, T., Horikawa, M., DiLillo, D. J., Yanaba, K., Venturi, G. M., Szabolcs, P. M., Bernstein, S. H., Magro, C. M., Williams, A. D., et al. (2011) · Blood · doi:10.1182/blood-2010-07-294249 · Cited by 1,104
Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17–producing cells
Koenen, H. J. P. M., Smeets, R. L., Vink, P. M., van Rijssen, E., Boots, A. M. H., & Joosten, I. (2008) · Blood · doi:10.1182/blood-2008-01-133967 · Cited by 736
Self-citationIdentification of a B cell signature associated with renal transplant tolerance in humans
Newell, K. A., Asare, A., Kirk, A. D., Gisler, T. D., Bourcier, K., Suthanthiran, M., Burlingham, W. J., Marks, W. H., Sanz, I., Lechler, R. I., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39933 · Cited by 678
Molecular Mechanism of Class Switch Recombination: Linkage with Somatic Hypermutation
Honjo, T., Kinoshita, K., & Muramatsu, M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.090501.112049 · Cited by 598
Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?
Bar‐Or, A., Fawaz, L., Fan, B., Darlington, P. J., Rieger, A., Ghorayeb, C., Calabresi, P. A., Waubant, E., Hauser, S. L., Zhang, J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21939 · Cited by 521
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359
Beers, S. A., French, R. R., Chan, H. T. C., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim, H., Cox, K. L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263533 · Cited by 335
Thurlings, R. M., Vos, K., Wijbrandts, C. A., Zwinderman, A. H., Gerlag, D. M., & Tak, P. P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080960 · Cited by 334
Avery, D. T., Bryant, V. L., Ma, C. S., de Waal Malefyt, R., & Tangye, S. G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1767 · Cited by 292
Good, K. L., Avery, D. T., & Tangye, S. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.2.890 · Cited by 279
Vo, A. A., Peng, A., Toyoda, M., Kahwaji, J., Cao, K., Lai, C.-H., Reinsmoen, N. L., Villicana, R., & Jordan, S. C. (2010) · Transplantation · doi:10.1097/tp.0b013e3181d21e7f · Cited by 248
Rituximab Therapy for Acute Humoral Rejection After Kidney Transplantation
Faguer, S., Kamar, N., Guilbeaud-Frugier, C., Fort, M., Modesto, A., Mari, A., Ribes, D., Cointault, O., Lavayssière, L., Guitard, J., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000261113.30757.d1 · Cited by 211
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
Vos, K., Thurlings, R. M., Wijbrandts, C. A., van Schaardenburg, D., Gerlag, D. M., & Tak, P. P. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22400 · Cited by 194
Chow, K. U., Sommerlad, W. D., Boehrer, S., Schneider, B., Seipelt, G., Rummel, M., Hoelzer, D. F., Mitrou, P. S., & Weidmann, E. (2002) · PubMed · Cited by 185
The anti-CD20 antibody rituximab reduces the Th17 cell response
van de Veerdonk, F. L., Lauwerys, B., Marijnissen, R. J., Timmermans, K., Di Padova, F., Koenders, M. I., Gutierrez-Roelens, I., Durez, P., Netea, M. G., van der Meer, J. W. M., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30314 · Cited by 180
Pharmacodynamics of Rituximab in Kidney Allotransplantation
Genberg, H., Hansson, A., Wernerson, A., Wennberg, L., & Tydén, G. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01497.x · Cited by 170
B Cell Survival in Intragraft Tertiary Lymphoid Organs After Rituximab Therapy
Thaunat, O., Patey, N., Gautreau, C., Lechaton, S., Frémeaux‐Bacchi, V., Dieu‐Nosjean, M., Cassuto, É., Legendre, C. M., Delahousse, M., Lang, P., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e3181735723 · Cited by 148
Beum, P. V., Peek, E. M., Lindorfer, M. A., Beurskens, F. J. M., Engelberts, P. J., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101189 · Cited by 140
Barberá‐Guillem, E., Nelson, M. B., Barr, B. L., Nyhus, J. K., May, K. F., Feng, L., & Sampsel, J. W. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/pl00006672 · Cited by 138
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
Jilani, I. B., O'Brien, S. M., Manshuri, T., Thomas, D. A., Thomázy, V. A., Imam, M., Naeem, S., Verstovšek, S., Kantarjian, H. M., Giles, F. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0055 · Cited by 136
Nakou, M., Katsikas, G., Sidiropoulos, P. I., Bertsias, G. K., Papadimitraki, E. D., Raptopoulou, A., Koutala, H., Papadaki, H. Α., Kritikos, H. D., & Boumpas, D. T. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2798 · Cited by 136
The 5-Year Outcome of ABO-Incompatible Kidney Transplantation With Rituximab Induction
Fuchinoue, S., Ishíi, Y., Sawada, T., Murakami, T., Iwadoh, K., Sannomiya, A., Koyama, I., Kubota, K., Tojimbara, T., Nakajima, I., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e31820f08e8 · Cited by 131
Immunologic effects of rituximab on the human spleen in immune thrombocytopenia
Audia, S., Samson, M., Guy, J., Janikashvili, N., Fraszczak, J., Trad, M., Ciudad, M., Seguin, V. L., Berthier, S., Petrella, T., et al. (2011) · Blood · doi:10.1182/blood-2011-03-344051 · Cited by 119
Eickenberg, S., Mickholz, E., Jung, E., Nofer, J., Pavenstädt, H., & Jacobi, A. M. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3835 · Cited by 72
Barbosa, R., Silva, S. P., Silva, S. L., Melo, A. C., Pedro, E., Barbosa, M. P., Santos, M. C. P., Victorino, R. M. M., & Sousa, A. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022848 · Cited by 69
Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis
Dörner, T., Isenberg, D. A., Jayne, D. R. W., Wiendl, H., Zillikens, D., & Burmester, G. R. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.08.007 · Cited by 65
B-cell immunotherapeutics: emerging roles in solid organ transplantation
Jordan, S. C., Kahwaji, J. M., Toyoda, M., & Vo, A. A. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834874f7 · Cited by 48
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
Cragg, M. S., Bayne, M., Tutt, A. L., French, R. R., Beers, S. A., Glennie, M. J., & Illidge, T. (2004) · Blood · doi:10.1182/blood-2004-05-1733 · Cited by 47
In Vitro Effects of Rituximab on the Proliferation, Activation and Differentiation of Human B Cells
Kamburova, E. G., Koenen, H. J. P. M., Boon, L., Hilbrands, L. B., & Joosten, I. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03833.x · Cited by 45
Self-citationSuccessful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab
Wermke, M., Bonin, M. V., Gehrisch, S., Siegert, G., Ehninger, G., & Platzbecker, U. (2009) · Haematologica · doi:10.3324/haematol.2009.017749 · Cited by 27
Apparent modulation of CD20 by rituximab: an alternative explanation
Cragg, M. S., Bayne, M. C., Illidge, T., Valerius, T., Johnson, P., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-12-4384 · Cited by 22
Cited by
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107725 · Cited by 610
CAR T-cell therapy in autoimmune diseases
Schett, G., Mackensen, A., & Mougiakakos, D. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01126-1 · Cited by 430
Mattoo, H., Mahajan, V. S., Della-Torre, E., Sekigami, Y., Carruthers, M., Wallace, Z. S., Deshpande, V., Stone, J. H., & Pillai, S. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.034 · Cited by 386
Metadata
- Authors
- Kamburova, E. G., Koenen, H. J. P. M., Borgman, K. J. E., ten Berge, I. J., Joosten, I., & Hilbrands, L. B.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 13
- Issue
- 6
- Pages
- 1503-1511
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1581336840
- Cited by
- 257
- References
- 34
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.